Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Postpartum haemorrhage, Pregnancy test, Ultrasound foetal
Clinical narrative: Postpartum haemorrhage; Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of POSTPARTUM HAEMORRHAGE (Postpartum haemorrhage) and MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) in a 33-year-old female patient (gravida 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025L20A and 041L20A) for COVID-19 vaccination.     Concurrent medical conditions included Juvenile RA (As a child, currently doing well) since 1990, Uveitis since 1994 and Glaucoma. Concomitant products included BRIMONIDINE TARTRATE (ALPHAGAN) and BIMATOPROST (LUMIGAN) for Glaucoma, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) from 01-Sep-2020 to an unknown date for Pregnancy, PREDNISOLONE for Uveitis, NAPHAZOLINE HYDROCHLORIDE (EYE DROPS [NAPHAZOLINE HYDROCHLORIDE]) for an unknown indication.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. The patient's last menstrual period was on 06-Sep-2020 and the estimated date of delivery was 13-Jun-2021. On 06-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). On an unknown date, the patient experienced POSTPARTUM HAEMORRHAGE (Postpartum haemorrhage). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  seventeenth week of the pregnancy. The vaginal delivery occurred on 07-May-2021, which was reported as Premature. For neonate 1, the birth weight was 2440 grams (5lbs 6oz). The outcome was reported as Pre-Term Birth w Complications. The patient had high risk pregnancy at 23 weeks and was put on partial bed rest on 16-Feb-2021, due to short cervix. Patient delivered a male baby at 34 weeks of gestation period. The length of the baby was 45.01 cm and circumference of head was 31 cm. Patient had retained placenta during delivery and post partum hemorrhage. . On 06-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) had resolved. At the time of the report, POSTPARTUM HAEMORRHAGE (Postpartum haemorrhage) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Oct-2020, Pregnancy test: positive (Positive) Positive. On 16-Feb-2021, Ultrasound foetal: abnormal (abnormal) Found hydro nephrosis on kidneys. On 15-Mar-2021, Glucose tolerance test: normal (normal) Normal.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient underwent In vitro fertilization on Sep-2020, embryo transfer was done and the first  In vitro fertilization  cycle worked. Estimated date of conception was on 25-Sep-2020. Number of fetus was found to be one.  Lab tests also included multiple ultrasound scans performed on 08-Dec-2020, 03-Feb-2021, 06-Mar-2021 and 04-May-2021,however, the results were not provided.  Perinatal complications included bilateral hydro nephrosis of kidneys and received care in NICU for 13 days. Post-partum 1 month abnormalities included left kidney hydro nephrosis.  Treatment information was not provided.   This case was linked to MOD-2021-261819 (Parent-Child Link).   See case MOD-2021-261819 for details regarding the child case.  Most recent FOLLOW-UP information incorporated above includes: On 19-Jul-2021: Follow up document received included patient demographics, pregnancy details, lab test, historical conditions, suspect drug dose details, concomitant medications, and additional event were updated.; Reporter's Comments: This is a case of product exposure during pregnancy with no associated AEs for this 33-year-old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.